A case study is the Alzheimer’s disease treatment Aduhelm, which drug maker Biogen laid to rest on Wednesday. “When searching for new medicines, one breakthrough can be the foundation that ...
a landmark Alzheimer’s disease treatment that also provoked controversy over conflicting data around its efficacy, the company said Wednesday. The FDA granted accelerated approval to the drug ...
Opens in a new tab or window Biogen will discontinue its controversial ... received full FDA approval in 2023, and donanemab, an investigational drug from Eli Lilly that's expected to be approved ...
The biopharmaceutical firm Biogen announced yesterday that it will discontinue developing and marketing the Alzheimer’s disease drug ... In approving the drug, the FDA acknowledged that there ...
Biotechnology company Biogen is abandoning Aduhelm, its questionable ... for the FDA voted resoundingly against Aduhelm's approval. Ten of 11 committee members voted against the drug, while ...
Biogen has announced it will give up ownership and halt sales of Aduhelm, an embattled Alzheimer's disease drug that was scrutinized following its 2021 approval. Biogen said it terminated a ...
Biogen is abandoning its lackluster Alzheimer’s disease ... did find enough evidence of the drug’s efficacy and that it would submit the drug for formal FDA approval. But other experts didn ...
FDA APPROVAL OF ALZHEIMER'S DRUG ADUHELM 'RIFE WITH IRREGULARITIES,' HOUSE REPORT SAYS To date, more than 6 million Americans are living with Alzheimer's, according to the Alzheimer's Association.
Aduhelm was the first new Alzheimer’s disease drug introduced in nearly two decades. The FDA granted accelerated approval for it in 2021. But regulators required an additional study before they ...
It was the first new Alzheimer’s drug approved in nearly 20 years and hit the market with a price tag of $56,000. But the evidence that the drug worked was scant, at best. House Democrats ...
For its part, Biogen said it will shift its focus to a newer Alzheimer's drug, Leqembi, which it markets in a partnership with Japan-based Eisai. Leqembi received FDA approval last year.